

# Solutions to address the unmet needs of the gMG patient journey in the US: A multistakeholder Delphi consensus study

AAN 2025, San Diego, CA, USA; April 5–9, 2025

Judith Thompson<sup>1</sup>, Victoria Mroczek<sup>2</sup>, Arthi Padmanabhan<sup>2</sup>

<sup>1</sup>UCB, Smyrna, GA, USA; <sup>2</sup>Real Chemistry, New York, NY, USA

## Introduction

- Our prior research with patients, caregivers, and patient advocates identified substantial unmet needs for the gMG community, which persist despite advances in treatment; these include delays in diagnosis, lack of recognition of the disease by HCPs, and barriers to accessing support networks and care<sup>1,2</sup>
- The research identified 13 potential solutions to these unmet needs related to improving the diagnostic journey, disseminating education and educational materials, and broadening access to care, resources, and support<sup>3,4</sup>
- This Delphi study aimed to build consensus around the most impactful and implementable solutions from a diverse HCP audience involved in the management of patients with gMG
- The objective was to build a list of consensus-driven, implementable solutions or interventions for addressing unmet needs, as validated by HCP stakeholders, to improve the lives of patients with gMG and the caregiver community in the US
  - To understand potential challenges to the implementation of solutions
  - To understand the complexities of proposed solutions and the reasons why they may not be deemed impactful

## Methods


- A comprehensive two-round Delphi survey was conducted with a multidisciplinary HCP group to garner consensus (**Figure 1** and **Table 1**)
- In Round 1, participants rated their level of agreement on each solution's suitability to address its associated unmet needs, provided the rationale for their assessment, and listed potential implementation challenges
- In Round 2, participants re-evaluated those solutions, considering the synthesized insights from Round 1

## Results

- A total of 23 HCPs (neurologists, NPs in a neurology setting, and PCPs) with experience of treating and managing patients with gMG in the US completed both Rounds 1 and 2
- Consensus (≥70% agreement) was achieved for all 13 proposed solutions (**Table 2**)
- The solutions spanned areas such as improving diagnostic accuracy, enhancing patient support systems, and fostering multidisciplinary care approaches
- The solutions with the highest consensus focused on addressing barriers to support networks and care, including increasing access and reducing wait times for neuromuscular specialists along with caregiver-focused support (**Figure 2**)
- The solutions with the lowest consensus focused on providing more holistic resources and support for patients' daily lives, including materials for special populations and employer conversation resources (**Figure 2**)

**Figure 1** Survey rounds' participants

Final results reflect feedback from MG care providers in the US who completed both Round 1 (April 25–June 6, 2024) and Round 2 (June 13–28, 2024) surveys



Data from participants who completed only Round 1 were excluded to ensure accurate longitudinal comparisons. The reduced sample for Round 2 is a result of the expected participant drop-off in multiround Delphi studies.<sup>5</sup>

**Table 1** Participant screening criteria


<b>General neurologists</b> <ul style="list-style-type: none"><li>Be board-certified/ licensed, or board-eligible in neurology</li><li>Be a general neurologist with either no sub-specialty or additional training in neuro-immunology, neuro-oncology, or behavioral neurology</li><li>Have treated or managed between 5 and 20 patients with MG within the past 12 months with ≥5 patients in MGFA classifications II (mild), III (moderate), or IV (severe)</li></ul>	<b>PCPs</b> <ul style="list-style-type: none"><li>Be board-certified/ licensed, or board-eligible in family medicine, internal medicine, or geriatric medicine</li><li>Have encountered ≥2 patients with MG over the previous 10 years</li><li>Have been involved with the ongoing care within the past 12 months of ≥1 patient with MG in MGFA classifications II (mild), III (moderate), or IV (severe)</li></ul>	<b>NPs</b> <ul style="list-style-type: none"><li>Primarily manage patients in a neurology practice setting</li><li>Have managed ≥5 patients with MG in MGFA classifications II (mild), III (moderate), or IV (severe)</li><li>Uphold three or more relevant responsibilities related to the management of patients with MG to ensure understanding of patient management</li></ul>
<b>Neurologists and PCPs must:</b> <ul style="list-style-type: none"><li>Have clinical practice experience ranging from 3 to 30 years</li><li>Devote at least 50% of their professional time to direct patient care</li></ul>		
<b>All respondents must:</b> <ul style="list-style-type: none"><li>Work in an academic/teaching hospital or center of excellence; community hospital; private, solo, or group practice or clinic; federally-qualified health center; or department of public health</li></ul>		

Note: Respondents were initially asked about MG during screening and were only introduced to gMG during the main survey.

**Table 2** gMG community-derived solutions

<b>Delayed diagnosis</b> <p><b>PCP symptom awareness:</b> Enhancing awareness for PCPs on diverse gMG symptoms</p> <p><b>Non-neurology specialist education:</b> Investing more in educating non-neurology specialists like rheumatologists, ophthalmologists, and psychologists to increase gMG awareness</p> <p><b>Educational materials for all:</b> Creating easy-to-understand educational materials (videos, Q&amp;As, support groups) for patients, caregivers, and HCPs</p>	<b>Lack of recognition</b> <p><b>Employer conversation resources:</b> Training/resources to manage conversations between employers and patients with gMG/caregivers</p> <p><b>Special population materials:</b> Targeted materials to support women of childbearing age and other special gMG patient populations</p> <p><b>Symptomatic burden materials for all:</b> Materials for patients, caregivers, and healthcare providers on the full symptomatic burden of gMG</p> <p><b>Self-care resources:</b> Resources for patients with gMG/caregivers to support self-care</p> <p><b>Psychological support:</b> Psychological support for patients with gMG/caregivers</p>	<b>Barriers to accessing support networks and care</b> <p><b>Expanded telehealth:</b> Expanded use of telehealth and other healthcare provider-based resources</p> <p><b>Neuromuscular specialist access:</b> Improved access to neuromuscular specialists</p> <p><b>Reduced neuromuscular wait time:</b> Reduced wait time to see neuromuscular specialists</p> <p><b>Caregiver support:</b> Caregiver-focused support</p> <p><b>Diverse distribution of materials:</b> The distribution of materials through a wider range of channels, such as websites and social media</p>
---	---	---

**Figure 2** Results of HCP validation research



HCP feedback on the solutions with the highest consensus suggests the **advancement of digital platforms could significantly improve the implementation and effectiveness** of associated solutions

HCP feedback on the solutions with the lowest consensus suggests a **disparity between HCPs' willingness to support patients clinically and their role in more holistic support of patients' daily lives**

## Summary and conclusions



Consensus (≥70% agreement) was achieved for all 13 proposed solutions spanning areas like improving diagnostic accuracy and timelines, raising MG awareness, enhancing patient support systems, and fostering multidisciplinary care approaches

Solutions with the highest consensus focused on addressing barriers to support networks and care, including increasing access and reducing wait times for neuromuscular specialists along with caregiver-focused support



The consensus indicates the importance and priority of implementation of the gMG community-derived solutions

These findings highlight critical areas for intervention and underscore the feasibility of implementing these solutions to improve the journey for patients with gMG and their caregivers

**Abbreviations:** gMG, generalized myasthenia gravis; HCP, healthcare provider; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; NP, nurse practitioner; PCP, primary care provider; Q&A, question and answer.

**Acknowledgments:** This study was funded by UCB. The authors acknowledge Ogilvy Health, London, UK, for editorial assistance, which was funded by UCB. The authors thank Veronica Porkess, PhD, of UCB for publication and editorial support. The authors thank the patients and their caregivers, in addition to the investigators and their teams who contributed to this study.

**Author disclosures:** Judith Thompson is an employee of UCB. Victoria Mroczek and Arthi Padmanabhan are employees of Real Chemistry. UCB has engaged Real Chemistry as a research partner to conduct a blinded research study.

**References:** 1. UCB. Collaborating for the myasthenia gravis community: identifying & addressing unmet needs for people living with myasthenia gravis in the United States. <https://www.ucb-usa.com/sites/default/files/2024-02/Community%20Unmet%20Needs%20Report%20and%20Materials%20282%29%20%281%29.pdf>. Accessed April 2025. 2. Law N, et al. Neurol Ther. 2021;10(2):1103–1125. 3. UCB Data on file. US advisory board meeting transcript. December 2022. 4. UCB Data on file. MG patients social listening research report. 2021. 5. Hall DA, et al. PLoS One. 2018;13(7):e0201378.

Please use this QR code to download a PDF of the poster.